1.Bertram, MY, Lim, SS, Barendregt, JJ, Vos, T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875–881.
2.Boulé, NG, Haddad, E, Kenny, GP, Wells, GA, Sigal, RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–1227.
3.Brazier, J, Roberts, , Deverill, M. The estimation of a preference based measure of health from the SF36. J Health Econ. 2002;21:271–292.
4.Briggs, A, Sculpher, M, Buxton, M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 1994;3:95–104.
5.Briggs, AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479–500.
6.Brun, JF, Bordenave, S, Mercier, J, Jaussent, A, Picot, MC, Préfaut, C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: A one-year controlled randomized trial. Diabetes Metab. 2008;34:258–265.
7.CADTH. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: CADTH; 2006.
8.Clarke, P, Gray, A, Holman, R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–349.
9.Clarke, PM, Gray, AM, Briggs, A, et al.A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 68) Outcomes Model. Diabetologia. 2004;47:1747–1759.
10.Coyle, D, Palmer, AJ, Tam, R. Economic evaluation of PioglitazoneHCl in the management of Type 2 Diabetes Mellitus in Canada. Pharmacoeconomics. 2002;20:31–42.
11.Doubilet, P, Begg, CB, Weinstein, MC, et al.Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making. 1985;5:157–177.
12.Eves, ND, Plotnikoff, RC. Resistance Training and Type 2 Diabetes. Considerations for implementation at the population level. Diabetes Care. 2006;29:1933–1941.
13.Goeree, R, Lim, ME, Hopkins, R, et al.Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can J Diabetes. 2009;33:35–45.
14.Herman, WH, Hoerger, TJ, Brandle, M, et al.The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–332.
15.Lamy, A, Yusuf, S, Pogue, J, Gafni, A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107:960–965.
16.Reid, RD, Tulloch, HE, Sigal, RJ, et al.Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: A randomised trial. Diabetologia. 2010;53:632–640.
17.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197.
18.Sapsford, R. Deputy Minister's response to the investigation into the Ministry of Health and Long-Term Care's decision-making concerning the funding of Avastin for colorectal cancer patients. Letter dated August 26th 2009.
19.Selvin, E, Marinopoulos, S, Berkenblit, G, et al.Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431.
20.Sigal, RJ, Kenny, GP, Boulé, NG, et al.Effects of aerobic exercise, resistance exercise, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med. 2007;147:357–369.
21.Snowling, NJ, Hopkins, WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis. Diabetes Care. 2006;29:2518–2527.
22.Stratton, IM, Adler, AI, Neil, HA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412.
23.Thomas, DE, Elliott, EJ, Naughton, GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968.
24.van Hout, BA, Al, MJ, Gordon, GS, et al.Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3:309–319.
25.Ware, JE, Snow, KK, Kolinski, M, Gandeck, B. SF-36 Health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.